CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 135 filers reported holding CRISPR THERAPEUTICS AG in Q1 2018. The put-call ratio across all filers is 3.59 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $217,000 | -32.6% | 2,870 | -0.1% | 0.02% | -36.1% |
| Q3 2021 | $322,000 | -30.8% | 2,873 | 0.0% | 0.04% | -30.8% |
| Q2 2021 | $465,000 | +32.9% | 2,873 | 0.0% | 0.05% | +30.0% |
| Q1 2021 | $350,000 | -20.5% | 2,873 | 0.0% | 0.04% | -25.9% |
| Q4 2020 | $440,000 | +83.3% | 2,873 | 0.0% | 0.05% | +54.3% |
| Q3 2020 | $240,000 | +133.0% | 2,873 | 0.0% | 0.04% | +105.9% |
| Q1 2019 | $103,000 | +151.2% | 2,873 | +101.6% | 0.02% | +142.9% |
| Q4 2018 | $41,000 | -34.9% | 1,425 | 0.0% | 0.01% | -30.0% |
| Q3 2018 | $63,000 | -25.0% | 1,425 | 0.0% | 0.01% | -28.6% |
| Q2 2018 | $84,000 | +29.2% | 1,425 | 0.0% | 0.01% | +27.3% |
| Q1 2018 | $65,000 | +97.0% | 1,425 | 0.0% | 0.01% | +120.0% |
| Q4 2017 | $33,000 | +32.0% | 1,425 | 0.0% | 0.01% | +25.0% |
| Q3 2017 | $25,000 | +8.7% | 1,425 | 0.0% | 0.00% | -20.0% |
| Q2 2017 | $23,000 | -25.8% | 1,425 | 0.0% | 0.01% | -28.6% |
| Q1 2017 | $31,000 | – | 1,425 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |